CMXHF News and Press, Csl Ltd

2024-06-21 15:50:11 ET Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to ente...

2024-06-11 13:59:31 ET Summary iShares MSCI Australia ETF provides targeted exposure to the Australian equities market, with a focus on large- and mid-cap companies. The EWA fund's top holdings include BHP Group, Commonwealth Bank of Australia, CSL Ltd., National Australia Bank, a...

2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...

2024-05-16 15:38:13 ET Summary Project $1M is a long-term buy-and-hold portfolio that aims to turn $275K into $1M by 2025 and outperform the S&P 500. 2024 has seen a positive start to the year. What's old is new - A new addition to the portfolio is a name that has been in ...

2024-04-24 08:31:26 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript Travere Therapeutics: Restructuring Away From Disaster Travere Therapeutics gains as EU backs kidney disease therapy Travere Therapeutics Q4...

2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...

2024-03-20 12:11:15 ET More on Kyowa Kirin Kyowa buyout Orchard wins FDA nod for rare disease therapy Historical earnings data for Kyowa Kirin Dividend scorecard for Kyowa Kirin Financial information for Kyowa Kirin Read the full article on Seeking ...

2024-03-07 09:19:59 ET More on CSL CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgrade) CSL Limited (CSLLY) Q2 2024 Earnings Call Transcript CSL Limited falls after Phase 3 setback for key trial Historical earnings data for CSL ...

2024-02-13 15:00:58 ET Summary CSL Limited achieved a +3% earnings beat for 1H FY 2024, and the company's full-year FY 2024 financial guidance was left unchanged. But CSL Limited's CSL112 trial results were unfavorable, which suggests that there might be an absence of meaningful p...

2024-02-13 00:53:08 ET CSL Ltd (CSLLY) Q2 2024 Earnings Conference Call February 12, 2024, 19:00 ET Company Participants Mark Dehring - Head, IR Paul McKenzie - MD, CEO & Executive Director William Mezzanotte - EVP & Head, Research and Development Her...